- Revolutionizing T Cell Immunotherapies
Eliminate Serum & Blood-Derived Components from Your Immunotherapy Applications
Pharma Tech Outlook interviewed our CEO Scott Deeter, who shares how InVitria is revolutionizing T cell immunotherapies.
InVitria offers the experience and expertise to help you maximize performance, reduce inconsistencies, better meet regulatory guidance, and stabilize your supply chain. From recombinant proteins to chemically defined, serum-free media, InVitria has solutions to take your immunotherapy to the next level.
For more information, visit our immunotherapy applications page to see how our proven products can transform your application.
Connect with our product applications team today to discuss solutions to your applications challenges